ICON
Founded in 1990 in Ireland, ICON is now a global CRO with over 14,000 employees in 40 countries. With a specialization focus on oncology and rare diseases, ICON started working on the first cell and gene therapy clinical trial in 2012 and now has a portfolio of over 40 CGT trials within the focused ACT business unit. Our advanced therapy group has over 300 dedicated team members that provide end to end clinical trial consulting and execution services. Adding the recent acquisition of Molecular MD to our central lab presents unique, single source capabilities for our cell and gene therapy trials. Our focus spans FIH to commercialization launch phases in clinical trials. We have deep experience in both autologous and allogeneic programs.
